Illumina targets cancer diagnostics

Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system. The idea is to develop sequencing diagnostics to go alongside cancer therapies being developed by AstraZeneca, Janssen Biotech and Sanofi.

Because tumours’ susceptibility to certain drugs often depends on whether they carry mutations in one or more of around 125 cancer-related genes, identifying the right patients can make treating cancers more successful, and mean the difference between success and failure in clinical trials. As a result, more and more drugs are being approved only in conjunction with a companion diagnostic test.

But most of these tests so far rely on biomarkers, or partial gene sequencing. The price of sequencing is dropping rapidly, and Illumina intends to develop tests that involve sequencing panels of whole genes, rather than searching individually for specific variants. The firm is aiming to take advantage of the fact that it currently sells the only ‘next-generation’ sequencer that is approved for clinical use to establish a dominant position in a nascent sequencing market. 

Related Content

Illumina fends off Roche hostile bid

27 January 2012 News Archive

news image

Roche aims to expand personalised medicine diagnostics by acquiring the gene sequencing leader

Oligonucleotide drugs step up

23 September 2015 Premium contentFeature

news image

Structural innovations are overcoming oligonucleotide drugs’ historical flaws, discovers Andy Extance

Most Commented

How do we solve a problem like Marie?

21 May 2015 The Crucible

news image

Women in science’s history deserve better treatment than myths and martyrdom, says Philip Ball

Chemistry at heart of VW emissions cheating

28 September 2015 News and Analysis

news image

Car firm dodged nitrogen oxide pollution limits using software that detected testing